By Davit Kirakosyan
Here is your Pro Recap of the biggest analyst picks and cuts you may have missed since Friday: downgrades at ASML and Applied Materials, upgrades at Abcam and West Pharmaceutical, and a buy initiation at LendingClub.
InvestingPro subscribers got this news before anyone else. Start your 7-day trial to get on board.
ASML (NASDAQ:ASML) shares fell more than 2% on Friday after New Street Research downgraded the company to Neutral from Buy.
Earlier last week, JPMorgan reiterated its Overweight rating on the stock, noting it believes that AI will continue to be an important driver of the company's growth in the future.
Year-to-date, shares are up more than 32%. The company is set to report its Q2/23 earnings next month. Street estimates stand at €4.94 for EPS and €7.23 billion for revenues.
New Street Research downgraded Applied Materials (NASDAQ:AMAT) to Neutral from Buy on Friday.
Earlier last week, Needham downgraded the company to Hold from Buy, stating that semicaps are overbought on AI hype.
Last month, the company reported its Q2 earnings, with EPS and revenues beating the consensus estimates.
Jefferies initiated coverage on LendingClub (NYSE:LC) with a Buy rating and a price target of $13.50, noting that the company is an early mover in the Fintech space with a deep operating history, bank charter, and a tech-enabled lending platform.
The firm anticipates Lending Club’s ROE to bottom in mid-2023 and provides several catalysts that are expected to boost both ROE and the company's valuation. Additionally, the firm highlighted the competitive advantages associated with the bank charter and a diversified growth strategy going forward.
BofA Securities upgraded Abcam (NASDAQ:ABCM) to Buy from Neutral with a price target of $25.00.
Shares jumped more than 17% on Friday after the company said it had received several takeover inquiries. This was followed by Jonathan Milner’s letter to shareholders calling for the removal of several board members. Milner, the founder of the company, is one of the largest investors in Abcam, with ownership of 6.3%.
BofA Securities upgraded West Pharmaceutical (NYSE:WST) to Buy from Neutral and raised its price target to $405.00 from $390.00.
Jump on the biggest news for your portfolio amid a barrage of market headlines: Always be the first to know with InvestingPro.
Begin trading today! Create an account by completing our form
At One Financial Markets we are committed to safeguarding your privacy.
Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.
Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.
Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.
By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.